1094 related articles for article (PubMed ID: 3018223)
1. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
2. Castration blocks chronic sulpiride-induced desensitization of striatal D1 receptor-stimulated adenylate cyclase activity in male rats.
Ryan-Jastrow T; Gnegy ME
J Pharmacol Exp Ther; 1989 Feb; 248(2):626-31. PubMed ID: 2521900
[TBL] [Abstract][Full Text] [Related]
3. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
Sesack SR; Bunney BS
J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
6. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
7. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
Roseboom PH; Gnegy ME
Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
[TBL] [Abstract][Full Text] [Related]
8. Hippocampal modulation of locomotor activity induced by focal activation of postsynaptic dopamine receptors in the core of the nucleus accumbens.
Rouillon C; Abraini JH; David HN
Hippocampus; 2007; 17(11):1028-36. PubMed ID: 17604350
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain.
Undie AS; Friedman E
J Pharmacol Exp Ther; 1990 Jun; 253(3):987-92. PubMed ID: 1972756
[TBL] [Abstract][Full Text] [Related]
10. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
11. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats.
Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M
Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349
[TBL] [Abstract][Full Text] [Related]
12. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
[TBL] [Abstract][Full Text] [Related]
13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
14. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway.
Santanavanich C; Ebadi M; Govitrapong P
J Pineal Res; 2005 Apr; 38(3):170-5. PubMed ID: 15725338
[TBL] [Abstract][Full Text] [Related]
16. Limbic pallidal adaptations following long-term cessation of dopaminergic transmission: lack of upregulation of dopamine receptor function.
Heidenreich BA; Mitrovic I; Battaglia G; Napier TC
Exp Neurol; 2004 Apr; 186(2):145-57. PubMed ID: 15026253
[TBL] [Abstract][Full Text] [Related]
17. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
Clark D; White FJ
Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
[TBL] [Abstract][Full Text] [Related]
18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
19. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.
Neisewander JL; Lucki I; McGonigle P
J Pharmacol Exp Ther; 1991 May; 257(2):850-60. PubMed ID: 2033524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
